Skip to main content

Table 6 Univariate analysis of predictors associated with mortality in patients with A. baumannii infection (N = 105)a

From: Acinetobacter baumannii: assessing susceptibility patterns, management practices, and mortality predictors in a tertiary teaching hospital in Lebanon

Characteristics

n (%)b

30-Days all-cause mortality

UOR (95% CI)

Pearson’s X2

Pd

Survived (26) n (%)c

Died (79) n (%)c

Age group (reference: 55–64 years)

 < 45

9 (8.6)

5 (55.6)

4 (44.4)

0.45 (0.10–2.12)

10.40

0.04e,f

 45–54

5 (4.8)

0 (0)

5 (100)

–

  

 55–64

25 (23.8)

9 (36)

16 (64)

–

  

 65–74

19 (18.1)

5 (26.3)

14 (73.7)

1.58 (0.43–5.82)

  

 ≥ 75

47 (44.8)

7 (14.9)

40 (85.1)

3.21 (1.05–10.10)

  

Sex (reference: female)

 Male

63 (60)

15 (23.8)

48 (76.2)

1.14 (0.46–2.79)

0.07

0.47

 Female

42 (40)

11 (26.2)

31 (73.8)

–

  

Department of infection acquisition (reference: internal medicine)

 Intensive care unit

83 (79)

11 (13.3)

72 (86.7)

8.18 (1.90–35.23)

33.26

< 0.001e,g

 Internal medicine

9 (8.6)

5 (55.6)

4 (44.4)

–

  

 Cardiac care unit

10 (9.5)

8 (80)

2 (20)

–

  

 Surgery

1 (1)

0 (0)

1 (100)

–

  

 Oncology

2 (1.9)

2 (100)

0 (0)

–

  

Past medical history (reference: no history of the related condition)

 Hypertension

68 (64.8)

16 (23.5)

52 (76.5)

1.20 (0.48–3.01)

0.157

0.69

 Diabetes mellitus

61 (58.1)

16 (26.2)

45 (73.8)

0.83 (0.33–2.05)

0.168

0.68

 Neutropenia

32 (30.5)

5 (15.6)

27 (84.4)

2.18 (0.74–6.42)

2.06

0.15

 Thrombocytopenia

30 (28.6)

2 (6.7)

28 (93.3)

6.59 (1.45–29.95)

7.38

< 0.001e

 Chronic kidney disease

36 (34.3)

6 (16.7)

30 (83.3)

2.04 (0.74–5.66)

1.92

0.17

 Coronary artery disease

33 (31.4)

9 (27.3)

24 (72.7)

0.82 (0.32–2.11)

0.163

0.69

Previous hospitalization within the last 3 months (reference: no)

 No

94 (89.5)

23 (24.5)

71 (75.5)

–

0.042

0.83

 Yes

11 (10.5)

3 (27.3)

8 (72.7)

0.86 (0.21–3.53)

  

Previous antibiotics use within the last 3 months (reference: no)

 No

93 (88.6)

24 (25.8)

69 (74.2)

–

0.477

0.49

 Yes

12 (11.4)

2 (16.7)

10 (83.3)

1.74 (0.36–8.51)

  

Invasive procedures within 30 days prior to infection acquisition (reference: no)

 No

7 (6.7)

4 (57.1)

3 (42.9)

–

4.22

0.04e

 Yes

98 (93.3)

22 (22.4)

76 (77.6)

4.61 (0.96–22.15)

  

Mechanical ventilation (reference: no)

 No

28 (26.7)

18 (64.3)

10 (35.7)

–

32.01

 < 0.001e

 Yes

77 (73.3)

8 (10.4)

69 (89.6)

15.53 (5.35–45.02)

  

Indwelling urethral catheterization (reference: no)

 No

32 (30.5)

9 (28.1)

23 (71.9)

–

0.27

0.59

 Yes

73 (69.5)

17 (23.3)

56 (76.7)

1.29 (0.5–3.31)

  

Central venous line (reference: no)

 No

47 (44.8)

19 (40.4)

28 (59.6)

–

11.20

0.001e

 Yes

58 (55.2)

7 (12.1)

51 (87.9)

4.94 (1.85–13.19)

  

Major surgery (reference: no)

 No

86 (81.9)

14 (16.3)

72 (83.7)

–

18.35

0.22

 Yes

19 (18.1)

12 (63.2)

7 (36.8)

0.11 (0.04–0.34)

  

Prolonged total parenteral nutrition (reference: no)

 No

82 (78.1)

22 (26.8)

60 (73.2)

–

0.85

0.35

 Yes

23 (21.9)

4 (17.4)

19 (82.6)

1.74 (0.53–5.69)

  

Renal replacement therapy (dialysis) (reference: no)

 No

85 (81)

24 (28.2)

61 (71.8)

–

2.89

0.08

 Yes

20 (19)

2 (10)

18 (90)

3.54 (0.76–16.44)

  

Source of infection (reference: soft tissue/wound infection)

 Respiratory infection

86 (81.9)

14 (16.3)

72 (83.7)

8.23 (2.34–28.88)

19.13

< 0.001e

 Soft tissue/wound infection

13 (12.4)

8 (61.5)

5 (38.5)

–

  

 Blood stream infection

5 (4.8)

3 (60)

2 (40)

1.07 (0.13–8.79)

  

 Urinary tract infection

1 (1)

0 (0)

1 (100)

–

  

Type of antimicrobial resistance (references: non-XDR and CSAB)

Non-XDR versus XDR

 Non-XDRh

61 (58.1)

20 (32.8)

41 (67.2)

–

5.03

0.02e

 XDR

44 (41.9)

6 (13.6)

38 (86.4)

3.09 (1.12–8.51)

  

CSAB versus CRAB

 CSAB

6 (5.7)

6 (100)

0 (0)

–

19.33

< 0.001e

 CRAB

99 (94.3)

20 (20.2)

79 (79.8)

–

  

Appropriateness of the antimicrobial therapy (reference: appropriate)

 Appropriate

56 (53.3)

23 (41.1)

33 (58.9)

–

17.13

< 0.001e

 Inappropriate

49 (46.7)

3 (6.1)

46 (93.9)

10.69 (2.96–38.57)

  
  1. CRAB, Carbapenem-resistance Acinetobacter baumannii; CSAB, Carbapenem-sensitive Acinetobacter baumannii; SD; standard deviation; UOR, unadjusted odds ratio; XDR, extensively drug resistant
  2. aSix patients (out of the 111) who failed to show up during the follow-up period were excluded
  3. bPercentages for the column
  4. cPercentages for the row
  5. dUnivariate analysis was conducted to test the associations between variables with mortality
  6. eStatistically significant (P < 0.05)
  7. fThe only significant difference was observed between the age group ≥ 75 and all other groups
  8. gThe only significant difference was observed between the intensive care unit and all other groups
  9. hIncludes non-multidrug resistant and multidrug resistant A. baumannii isolates
Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us